@gerryfsmith

Writer. Previously at Bloomberg News, HuffPost, Chicago Tribune. Email: [email protected]

 New York
gerry-smith.com/
Joined August 2008
  • Tweets946
  • Following1.2K
  • Followers8.7K
16Media
Parents are getting their kids vaccinated early, worried that recent moves by RFK Jr could limit access to childhood shots. bloomberg.com/news/articles/…

RFK Jr. Is Scaring Parents Into Asking Doctors for Early Shots

Pediatricians weigh the risks of vaccinating ahead of schedule with threat of shot shortages looming.

bloomberg.com
7
3
32
31,018
For @CNBC, I wrote about the cystic fibrosis patients who have been left behind www-cnbc-com.cdn.ampproject.…

For the final 10% of cystic fibrosis patients, the breakthrough still hasn't come

For the final 10% of cystic fibrosis patients who cannot benefit from breakthrough drugs, Emily's Entourage is funding research to find treatments.

www-cnbc-com.cdn.ampproject.org
1
2
2
455
Gerry Smith retweeted
Emma G. Fitzsimmons@emmagfOct 1
Cute Delivery Robots Have Invaded New Jersey. Not Everyone Is Charmed, by @gerryfsmith: nytimes.com/2026/10/01/nyreg…

Cute Delivery Robots Have Invaded New Jersey. Not Everyone Is Charmed. (Gift Article)

The machines have conquered Jersey City’s sidewalks, and Hoboken is the next target. But skepticism about artificial intelligence has forced the robot horde to proceed with caution.

nytimes.com
1
2
8
1,411
Gerry Smith retweeted
✨kvb✨@kristenvbrownSep 30
Biotech founder Cathy Tie calls editing human embryos a "moral imperative." Scientists say the work isn't ready, and that even a perfect tool can't guarantee safety. That raises a question: What would safe enough actually look like? My story @WIRED wired.com/story/biotech-foun…

A Biotech Founder Makes the Moral Case for Gene-Editing Human Embryos

The practice of editing the genes of embryos remains highly controversial and risky, but Origin Genomics founder Cathy Tie argues its a “moral imperative” to address hereditary diseases.

wired.com
1
1
171
Powerful story by @emmagf who puts a human face on the dangers of electric bikes and scooters nytimes.com/2026/09/30/nyreg…

As E-Bikes and Scooters Surge on New York Streets, So Do Fatal Crashes

More than two dozen people have died in crashes involving electric bikes and scooters in New York City this year. Officials are moving to address a growing safety crisis.

nytimes.com
1
9
660
My latest for @cnbc: NIH funding cuts delayed a promising childhood brain cancer trial. Patients lost time they didn’t have cnbc.com/2026/09/25/nih-cuts…

NIH funding cuts delayed a promising childhood brain cancer trial. Patients lost time they didn't...

A delayed clinical trial underscores the stakes of federal research funding cuts for children with DIPG, a deadly brain tumor with few treatment options.

cnbc.com
1
4
2
560
Gerry Smith retweeted
Emma G. Fitzsimmons@emmagfSep 18
The $25 Million Plan to Raze a Beach House and Put Up a Parking Lot by @gerryfsmith: nytimes.com/2026/09/18/reale…

The $25 Million Plan to Raze a Beach House and Put Up a Parking Lot (Gift Article)

Southampton is buying a beachfront mansion and tearing it down to improve beach access. And it says it isn’t stopping with just one house.

nytimes.com
1
5
3
9
3,117
For @ObserverUK, I spent a day with Anthony Scaramucci in the Long Island town where he grew up. We talked about Trump, Mamdani, podcasting and getting fired from the White House after 11 days. "You become more human to everybody with a few failures.” observer.co.uk/news/observer…

Anthony Scaramucci: ‘Getting my ass kicked in Washington,...

On a tour of the blue-collar Long Island community where he grew up, the financier turned Trump spokesman discusses his new book on where America went wrong, podcast stardom and why being fired from...

observer.co.uk
6
5
5,605
A rare disease is taking his vision. A gene therapy could help — if he can get it. My story for @cnbc: cnbc.com/2026/09/10/rare-dis…

A rare disease is taking his vision. A gene therapy could help — if he can get it

A well-connected family’s fight to access a potential treatment for their son highlights the barriers most rare disease patients struggle to overcome.

cnbc.com
3
3
618
Is that fireplace real or AI? Listings on Zillow and StreetEasy are littered with homes with fake fireplaces, improved views and virtual landscaping, raising false advertising concerns nytimes.com/2026/09/08/reale…

Is That Fireplace Real or A.I.?

Listing sites are littered with homes with fake fireplaces, improved views and virtual landscaping, raising false advertising concerns.

nytimes.com
3
2
9
3,136
Gerry Smith retweeted
✨kvb✨@kristenvbrownJul 23
Women were once told to suffer through menopause in silence. Now they’re navigating a cacophony of supplements, hormone subscriptions, influencers and dubious promises. My new story on how the menopause boom is leaving women behind: bloomberg.com/news/features/…

The Menopause Gold Rush Is Failing Women

While startups and supplements are making billions, the healthcare mainstream hasn’t kept pace with women’s midlife needs.

bloomberg.com
1
1
1
9
1,168
Gerry Smith retweeted
Emma G. Fitzsimmons@emmagfJul 3
Come for Zohran Mamdani’s Taylor Swift playlist, stay for Bill de Blasio’s favorite song about “the way past lovers linger in our memories for years or even decades.” nytimes.com/2026/07/02/nyreg…

Yes, Mamdani Is a Taylor Swift Fan. These Are His Top 12 Songs. (Gift Article)

Ahead of Taylor Swift’s wedding celebration in Manhattan, Mayor Zohran Mamdani revealed that he is a bigger fan of her music than previously known.

nytimes.com
2
4
1
15
5,874
Gerry Smith retweeted
Emma G. Fitzsimmons@emmagfJun 10
This Parking Spot Is Free. Should It Be? with @stefanoschen and @edenweingart: nytimes.com/interactive/2026…

This Parking Spot Is Free. Should It Be? (Gift Article)

There are about three million parking spaces in New York City, but drivers are always struggling to find one that’s open. Can the system be fixed?

nytimes.com
8
7
4
22
3,885
Scoop: Blackstone is providing as much as $1.3 billion to Apogee to help the biotech company advance a potential competitor to Dupixent bloomberg.com/news/articles/…

Blackstone Injecting Up to $1.3 Billion in Apogee for Skin Drug

Blackstone Inc. is providing as much as $1.3 billion in financing to Apogee Therapeutics Inc. to help the biotech company advance a potential competitor to the blockbuster drug Dupixent.

bloomberg.com
1
2
2,205
In one of the first moves of the post-Makary era, FDA has scheduled a meeting of outside experts to discuss Moderna's controversial mRNA flu vaccine application. w/ @gerryfsmith bloomberg.com/news/articles/…

FDA Plans Rare Advisory Hearing to Debate Moderna’s Flu Shot

Moderna Inc.’s experimental flu shot made with mRNA technology will be reviewed by a Food and Drug Administration advisory panel next month, a sign that the agency may be increasing transparency into...

bloomberg.com
2
7
2
21
6,368
New: US officials are working with a small biotech company, Mapp Biopharmaceutical, to provide an experimental treatment that may be used in patients exposed to Ebola. google.com/url?q=https://www…

US Enlists Small Biotech for Experimental Ebola Treatment

US officials are working with a small biotech company to provide an experimental treatment that may be used in patients exposed to Ebola, according to a person familiar with the matter.

bloomberg.com
1
4
551
New: Can AI Drug Development Live Up to the Hype? The industry is pouring billions into the idea that it can make the process faster and more predictable, but there's reason for caution: bloomberg.com/news/articles/…

Can AI Drug Development Live Up to the Hype?

Big Pharma is pouring money into tech-devised treatments, but the verdict is out on whether they’ll actually work.

bloomberg.com
3
10
12,582
More turnover at FDA: The agency is replacing the head of its vaccine and gene therapy division with FDA adviser Karim Mikhail, while current acting director Katherine Szarama will stay at the agency. Other changes here: bloomberg.com/news/articles/…

FDA Revamp Begins With the Departure of a Marty Makary Ally

Several key allies of former Food and Drug Administration commissioner Marty Makary are departing their posts, according to people familiar with the matter, as the Trump administration attempts to...

bloomberg.com
Rachel Cohrs Zhang
@rachelcohrsMay 15
New: FDA's top drug regulator Tracy Beth Høeg is departing the agency following Marty Makary's exit earlier this week. CDER deputy director Mike Davis will serve as acting director bloomberg.com/news/articles/…

FDA Revamp Begins With the Departure of a Marty Makary Ally

Several key allies of former Food and Drug Administration commissioner Marty Makary are departing their posts, according to people familiar with the matter, as the Trump administration attempts to...

bloomberg.com
3
10
2
19
8,069
Marty Makary’s exit as head of the FDA is giving the biotech industry hope for stability after months of turmoil. "It’s been a circus," one analyst said, adding that he's looking forward to "a new leader and less drama." bloomberg.com/news/articles/…

Makary’s Exit From FDA Gives Biotech Hope the ‘Circus’ Is Over

Marty Makary’s exit as head of the Food and Drug Administration is giving the biotech industry hope for stability after months of turmoil.

bloomberg.com
1
11
28
6,271
President Donald Trump plans to oust FDA Commissioner Marty Makary following tumult at the agency (confirming @l_e_whyte) 🎁: bloomberg.com/news/articles/…

Trump Plans to Fire FDA’s Makary After Tumult at Agency

President Donald Trump plans to fire Food and Drug Administration Commissioner Marty Makary, following months of chaos at one of the country’s most important health agencies, according to a person...

bloomberg.com
6
10
2
41
5,929
Scoop: Blackstone is investing $250 million in the biotech startup Anagram Therapeutics, part of the private equity giant’s strategy to own more cutting-edge drugmakers. bloomberg.com/news/articles/…

Blackstone Invests $250 Million in Biotech Anagram Therapeutics

Blackstone Inc. is investing $250 million in the biotech startup Anagram Therapeutics Inc., part of the private equity giant’s strategy to own more cutting-edge drugmakers.

bloomberg.com
1
1
876
Load more